Print PRINT
X
DuoVisc® Viscoelastic System

Learn More About DuoVisc® Viscoelastic System

From everyday cases to complex situations, the DuoVisc® Viscoelastic System has you covered. Featuring the genuine protection of VISCOAT® OVD and the space maintenance of ProVisc® OVD, DuoVisc® Viscoelastic System provides one system without compromise.

DuoVisc®

On this page, you'll find quick facts about DuoVisc® Viscoelastic System, brochures, product inserts, and more.

DuoVisc® Viscoelastic System Product Summary

VISCOAT® OVD

Size:0.35 or 0.50 ml
Components:3% Sodium Hyaluronate, 4% Chondroitin Sulfate
Molecular Weight:600,000 Daltons
Dynamic Viscosity:40,000 cps
CDI:3.5
Classification:Medium Viscosity Dispersive
Osmolality:325

ProVisc® OVD

Size:0.40 or 0.55 ml
Components:1% Sodium Hyaluronate
Molecular Weight:2,400,000 Daltons
Dynamic Viscosity:39,000 cps
CDI:43
Classification:Viscosity Cohesive
Osmolality:310

DuoVisc® Viscoelastic System Advantages1

VISCOAT® OVD

  • Better endothelial cell protection
  • Superior clarity and visualization
  • Superior retention during lens removal

ProVisc® OVD

  • Superior anterior capsule dome maintenance
  • Proven mechanical protection of space maintenance
  • Easy to remove after procedure

Download DuoVisc® Viscoelastic System Product Information.

View Important Product Information for
DisCoVisc® OVD+

DisCoVisc® OVD

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

Description: DisCoVisc® Ophthalmic Viscosurgical Device has an intermediate cohesive/dispersive index (CDI) and can best be described as the first viscous dispersive viscoelastic and is optimized for the entire surgical procedure.

Indications: DisCoVisc® Ophthalmic Viscosurgical Device is indicated for use during surgery in the anterior segment of the eye. It is designed to create and maintain space, to protect the corneal endothelium and other intraocular tissues and to manipulate tissues during surgery. It may also be used to coat intraocular lenses and instruments during cataract extraction and IOL insertion.

Warnings: Failure to follow assembly instructions or use of an alternate cannula may result in cannula detachment and potential patient injury.

Precautions: Precautions are limited to those normally associated with the surgical procedure being performed. Although sodium hyaluronate and sodium chondroitin sulfate are highly purified biological polymers, the physician should be aware of the potential allergic risks inherent in the use of any biological material.

Adverse Reactions: DisCoVisc® Ophthalmic Viscosurgical Device was very well tolerated in nonclinical and clinical studies. A transient rise in intraocular pressure in the early postoperative period may be expected due to the presence of sodium hyaluronate, which has been shown to effect such a rise. It is therefore recommended that DisCoVisc® OVD be removed from the anterior chamber by thorough irrigation and/or aspiration at the end of surgery to minimize postoperative IOP increases. Do not overfill anterior chamber.

Attention: Reference the Physician Labeling/Directions for Use for a complete listing of indications, warnings and precautions.

DUOVISC® OVD +

DUOVISC® OVD

Description: DUOVISC® Viscoelastic System is designed to give two Viscoelastic materials with different physico-chemical properties that can be used differently and/or sequentially to perform specific tasks during a cataract procedure. DUOVISC® Viscoelastic System consists of VISCOAT® Ophthalmic Viscosurgical Device and PROVISC® Ophthalmic Viscosurgical Device.

Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician.

Description: VISCOAT® (Sodium Chondroitin Sulfate – Sodium Hyaluronate) Ophthalmic Viscosurgical Device

Indications: VISCOAT® OVD is indicated for use as an ophthalmic surgical aid in anterior segment procedures including cataract extraction and intraocular lens (IOL) implantation. VISCOAT® OVD maintains a deep anterior chamber during anterior segment surgeries, enhances visualization during the surgical procedure, and protects the corneal endothelium and other ocular tissues. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery.

Warnings: Failure to follow assembly instructions or use of an alternate cannula may result in cannula detachment and potential patient injury.

Precautions: Precautions are limited to those normally associated with the surgical procedure being performed. Although sodium hyaluronate and sodium chondroitin sulfate are highly purified biological polymers, the physician should be aware of the potential allergic risks inherent in the use of any biological material.

Adverse Reactions: VISCOAT® OVD has been extremely well tolerated in human and animal studies. A transient rise in intraocular pressure in the early postoperative period may be expected due to the presence of sodium hyaluronate, which has been shown to effect such a rise. It is therefore recommended that VISCOAT® OVD be removed from the anterior chamber by thorough irrigation and/or aspiration at the end of surgery to minimize postoperative IOP increases. Do not overfill anterior chamber.

ATTENTION: Reference the Physician Labeling/Directions for Use for a complete listing of indications, warnings and precautions.

Description: PROVISC® (Sodium Hyaluronate) Ophthalmic Viscosurgical Device

Indications: PROVISC® OVD is indicated for use as an ophthalmic surgical aid in the anterior segment during cataract extraction and intraocular lens (IOL) implantation. Ophthalmic viscoelastics serve to maintain a deep anterior chamber during anterior segment surgery allowing reduced trauma to the corneal endothelium and surrounding ocular tissues. They help push back the vitreous face and prevent formation of a flat chamber during surgery.

Precautions: Postoperative increases in intraocular pressure have been reported with sodium hyaluronate products. The IOP should be carefully monitored and appropriate therapy instituted if significant increases should occur. It is recommended that PROVISC® OVD be removed by irrigation and/or aspiration at the close of surgery. Do not overfill anterior chamber. Although sodium hyaluronate is a highly purified biological polymer, the physician should be aware of the potential allergic risks inherent in the use of any biological material; care should be used in patients with hypersensitivity to any components in this material. Cannula assembly instructions should be followed to prevent patient injury.

Adverse Reactions: Postoperative inflammatory reactions such as hypotony and iritis have been reported with the use of ophthalmic viscoelastics, as well as incidents of corneal edema, corneal decompensation, and a transient rise in intraocular pressure. It is therefore recommended that PROVISC® OVD be removed from the anterior chamber by thorough irrigation and/or aspiration at the end of surgery to minimize postoperative IOP increases. Do not overfill anterior chamber.

Attention: Reference the Physician Labeling/Directions for Use for a complete listing of indications, warnings and precautions.

[an error occurred while processing this directive]

GRIESHABER® Aspheric Lens

Indications for Use: The GRIESHABER® DSP Aspheric Macular Lens is used to visualize the fundus and retinal structures during vitreoretinal surgery. It is designed as a self-retaining contact lens to allow hands-free operation.

Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician.

Warnings and Precautions:

  • The device may be used only by well trained physicians and personnel.
  • Potential risk from reuse or reprocessing include: reduced optical quality, surface damage on the optics, and foreign particle introduction to the eye.
  • The surgeon’s team has to ensure that sufficient viscous fluid is available throughout usage of the lens for continuous humidification of the cornea.

Attention: Reference the Directions for Use for a complete listing of indications, warnings, and precautions.